Generic Metoclopramide Lawsuit Dismissed Against Makers of Reglan

A federal judge has dismissed Wyeth, Inc. and Schwarz Pharma, Inc. from a metoclopramide lawsuit filed in Texas over the development of the movement disorder tardive dyskinesia, as plaintiff never used the name brand medication Reglan sold by the drug makers. The case will proceed against only Activis-Elizabeth, L.L.C., which manufactured the generic Reglan version taken by the plaintiff.

The lawsuit was brought by Judith Finnicum last August in the U.S. District Court for the Eastern District of Texas, alleging that she developed uncontrollable movements after taking generic metoclopramide to treat gastrointestinal problems.

While the complaint included Wyeth and Schwarz, which originally developed metoclopramide and sold the medication as Reglan, U.S. District Judge Marcia A. Crone granted a summary judgment motion to dismiss the two drug makers from the litigation, indicating that the case will move forward only against Actavis-Elizabeth. According to a scheduling order in the generic metoclopramide lawsuit, the remaining parties are expected to be ready to try the case by early January 2011.

Did You Know?

Change Healthcare Data Breach Impacts Millions of Customers

A massive Change Healthcare data breach exposed the names, social security numbers, medical and personal information of potentially 100 million Americans, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

A number of similar lawsuits over generic metoclopramide and Reglan are pending in various courts throughout the United States against Wyeth, Schwarz and a number of generic drug makers. The cases all involve similar allegations that side effects of metoclopramide caused tardive dyskinesia, and that the drug makers failed to adequately warn about the increased risk associated with long-term use of the medication.

In June 2009, the U.S. Judicial Panel on Multidistrict Litigation denied a request to consolidate the federal Reglan litigation. Therefore, all federal cases are proceeding as individual cases in courts across the country.

Reglan was originally introduced by Wyeth in 1989, and the drug company continued to market and distribute the drug through late December 2001, when Schwarz acquired the rights to Reglan. Schwarz continued to manufacture and distribute the drug until 2008, when they ceased production, leaving only generic metoclopramide versions. Since the mid-eighties metoclopramide generic has been manufactured by a number of companies.

While metoclopramide is only approved for short-term treatment of gastrointestinal disorders, like diabetic gastroparesis, gastroesphageal reflux (GERD) and delayed gastric emptying, it is often prescribed for longer periods of time given the chronic persistence of those ailments. Use of metoclopramide for more than 12 weeks has been shown to increase the risk of tardive dyskinesia and other movement disorders, and plaintiffs allege that Wyeth and Schwarz failed to adequately research their medication and attempted to minimize the risk.

Tardive dyskinesia is a neurological disorder that causes repetitive and involuntary movements of the lower face and limbs. Symptoms can include repeated grimacing, chewing, smacking of lips, rapid eye movements and impaired finger movements. There is no known effective treatment for the problems from metoclopramide, and the involuntary movements often persist even after use of the drug has stopped, contrary to what was suggested on the warning labels for Reglan and generic metoclopramide drugs.

In February 2009, the FDA required that the manufacturers of all metoclopramide-containing drugs add a “black box” warning about the risk of metoclopramide tardive dyskinesia problems. In addition, the manufacturers were required to develop a mitigation and risk evaluation strategy to help ensure that patients are made aware of the potential side effects of metoclopramide.

2 Comments

  • ShenikaMarch 30, 2011 at 2:14 pm

    I was given reglan in the hospital threw IV and it change my life for the worse. I grinded half of my teeth down to the bone.I have nightmares of this happenjing to me againwith a different medication. I had muscle spasms all over my body and my daughters had to witness that

  • LisaOctober 9, 2010 at 4:33 pm

    Is there a class action suit against the makers of metoclopramide?

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Lawyers Propose MDL Trial Dates for Baby Formula NEC Lawsuit Starting in May 2025
Lawyers Propose MDL Trial Dates for Baby Formula NEC Lawsuit Starting in May 2025 (Posted yesterday)

A series of four bellwether claims in the baby formula NEC lawsuit MDL will be ready to go before a federal juries in May 2025, August 2025, November 2025 and February 2026 according to a proposed trial schedule agreed upon by both plaintiffs and defendants.

AngioDynamics Port Catheter Lawsuit MDL Established in Southern District of California
AngioDynamics Port Catheter Lawsuit MDL Established in Southern District of California (Posted 2 days ago)

U.S. JPML has transferred all AngioDynamics port catheter lawsuits to the U.S. District Court for the Southern District of California, for coordinated discovery and pretrial proceedings as part of a federal MDL (multidistrict litigation).